Replies to post #153126 on Biotech Values

[oc631]

RE:IL28B



The irrelevance of IL28B status is a fine example of the changes in the oral HCV space.

Considering the disparity between results we are seeing in GT2 and GT3 patients I feel it would be prudent for the FDA to require the genotypes to be tested separately. The grouping of GT2 and GT3 under oral therapy is now becoming a dated clinical practice of prior interferon-based treatment.